SCHEMBL16005234

SCHEMBL16005234

O=[N+]([O-])c1cc[c]c(S)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.46
LMNA P02545 2/20 0.46
ALDH1A1 P00352 9/20 0.41
TDP1 Q9NUW8 5/20 0.41
HSD17B10 Q99714 1/20 0.41
ALOX15 P16050 2/20 0.39
PTPRC P08575 1/20 0.39
S100A4 P26447 1/20 0.39
ACHE P22303 1/20 0.39
GPR35 Q9HC97 2/20 0.38
CYP3A4 P08684 2/20 0.38
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HIF1A Q16665 1/20 0.38
CYP19A1 P11511 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26325 0.77 TSHR (0.48) TSHRLMNAALDH1A1TDP1HSD17B10
SCHEMBL3591508 0.75 ALDH1A1 (0.48) TSHRLMNAALDH1A1TDP1HSD17B10
SCHEMBL887743 0.75 TSHR (0.48) TSHRLMNAALDH1A1TDP1HSD17B10
SCHEMBL10383515 0.75 TSHR (0.46) TSHRLMNAALDH1A1TDP1HSD17B10
SCHEMBL1473759 0.75 ALDH1A1 (0.47) TSHRLMNAALDH1A1TDP1HSD17B10
SCHEMBL455697 0.75 ALDH1A1 (0.50) TSHRLMNAALDH1A1TDP1HSD17B10
SCHEMBL57963 0.75 HSD17B10 (0.50) TSHRLMNAALDH1A1TDP1HSD17B10
SCHEMBL146835 0.75 ALDH1A1 (0.47) TSHRLMNAALDH1A1TDP1HSD17B10
Water SCHEMBL28995322 0.75 TSHR (0.46) TSHRLMNAALDH1A1TDP1HSD17B10
SCHEMBL4600228 0.75 ALDH1A1 (0.46) TSHRLMNAALDH1A1TDP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2964661-B1 METALLOCENE COMPOUNDS AND LABELED MOLECULES COMPRISING THE SAME FOR IN VIVO IMAGING APTENIA S R L (IT) 2018-01-10 EP disclosed
US-9399077-B2 Metallocene compounds and labeled molecules comprising the same for in vivo imaging APTENIA S.R.L. (IT) 2016-07-26 US disclosed
US-20160008495-A1 Metallocene Compounds and Labeled Molecules Comprising the Same for In Vivo Imaging APTENIA S.R.L. (IT) 2016-01-14 US disclosed
EP-2774930-A1 Metallocene compounds and labeled molecules comprising the same for in vivo imaging. Aptenia S.R.L. (IT) 2014-09-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160008495-A1 Metallocene Compounds and Labeled Molecules Comprising the Same for In Vivo Imaging MEN1, MPI, TFRC TSHR 487/4885LMNA 2813/4885ALDH1A1 3718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.